nanoTherics’s primary business is supply of improved scientific devices and associated products to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The Company’s products follow from >30 years combined cutting edge research into magnetic nanoparticle use conducted at Keele University and University of Florida and apply a patent-pending technology using nanoparticles and magnetic fields to facilitate enhanced delivery of biomolecules, such as DNA, into living cells. The medium to long-term opportunity for this approach relates to more effective non-viral gene therapy, an area demanding safer technology to treat genetic diseases such as cystic fibrosis. Dr Linda Cammish, Chief Executive Officer, said, “We are delighted to be offering this new product to enable our customers to improve their transfection efficiencies with even the most hard to transfect cells”. She added, “We are committed to product development to meet our customers needs and aim to introduce a range of additional products throughout 2009. The in-vivo potential of this technology is particularly exciting, which is an area we will be placing particular focus on”.”
About nanoTherics
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research conducted at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate improved delivery of foreign molecules, including DNA, into living cells. nanoTheric’s gene transfection studies have shown significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst maintaining viability of transfected cells. These key attributes afford a significant competitive advantage over currently available systems.
nanoTherics’s mission is to position its novel gene transfection technology as the new “gold standard” for transfection, underpinning research and development of current and future gene therapy programmes.
